Afatinib (BIBW2992)

Catalog No.S1011

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Cited by 180 Publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )
Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )
Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )
Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )
Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )
PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )
Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )
Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmwUVVNUUN3ME2wMlAxPTd{IN88US=>	MmXDV2FPT0WU
KASUMI-1	NU\rfmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnPTWM2OD1yLkCwPVEyKM7:TR?=	MVPTRW5ITVJ?
HCC2218	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEC5PFch\|ryP	MVPTRW5ITVJ?
KARPAS-45	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPOTY1KSzVyPUCuNFE3PzFizszN	Mn;XV2FPT0WU
HSC-4	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rSOGlEPTB;MD6wNVc1QCEQvF2=	MXXTRW5ITVJ?
CHL-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrWXIRKSzVyPUCuNFE5OzlizszN	M1\MUnNCVkeHUh?=
KY821	NIHVb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\NS2RKSzVyPUCuNFIxPiEQvF2=	Mlq2V2FPT0WU
NCI-N87	M1nIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHX5RolKSzVyPUCuNFI4PzNizszN	MWPTRW5ITVJ?
DOK	NXLU[Ip4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXOwS4E3UUN3ME2wMlA{OTl2IN88US=>	M{LXPXNCVkeHUh?=
DSH1	M2Dhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfUTWM2OD1yLkCzN\|E1KM7:TR?=	MkjnV2FPT0WU
MDA-MB-175-VII	NWX3d\|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuydJlKSzVyPUCuNFM1OTZizszN	NV;PdVl[W0GQR1XS
NCI-H2170	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMEO3Nlgh\|ryP	MmfqV2FPT0WU
BT-474	NYXyco1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LOUmlEPTB;MD6wOFk5PiEQvF2=	M{nnVHNCVkeHUh?=
EFO-27	M{LGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rUS2lEPTB;MD6wOVE5OiEQvF2=	NI\oPFBUSU6JRWK=
NCI-H720	M{DCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rGcGlEPTB;MD6wOVMzPSEQvF2=	MXXTRW5ITVJ?
PC-14	NIn6OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYKxbm5UUUN3ME2wMlA2PjZ6IN88US=>	MXzTRW5ITVJ?
EC-GI-10	NXHUUWF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnMTXlKSzVyPUCuNFU6OTJizszN	MWjTRW5ITVJ?
KYSE-450	M1T0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkToTWM2OD1yLkC1PVc5KM7:TR?=	MYPTRW5ITVJ?
BPH-1	NGe3d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ixd2lEPTB;MD6wOVk5QCEQvF2=	MnHXV2FPT0WU
NCI-H292	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwME[wPUDPxE1?	Mo\tV2FPT0WU
H9	NVTBZZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLrcGRWUUN3ME2wMlA4OTN{IN88US=>	NX3yTmJrW0GQR1XS
NCI-H526	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfFcYNSUUN3ME2wMlA4QDJ\|IN88US=>	MmjTV2FPT0WU
NCI-H1623	NH7sVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHLfnJoUUN3ME2wMlA5ODJ3IN88US=>	NV\CPZJ2W0GQR1XS
KYSE-140	M4LReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\uTWM2OD1yLkC4N\|Mh\|ryP	NI\yXHBUSU6JRWK=
Ca9-22	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEizOVMh\|ryP	NVXYbmtYW0GQR1XS
AU565	M3\U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfxTWM2OD1yLkC4OVA1KM7:TR?=	NU\NUYZMW0GQR1XS
ZR-75-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHM[WpKSzVyPUCuNFk2PDVizszN	NXTCdZZFW0GQR1XS
NCI-H1770	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGb3RKSzVyPUCuNVAzQCEQvF2=	MoL1V2FPT0WU
LB2241-RCC	NV2ycGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS2TWM2OD1yLkGwPFg1KM7:TR?=	M2j3RXNCVkeHUh?=
CAL-39	NIDUeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33HfGlEPTB;MD6xNVc6OiEQvF2=	NYLJVWNZW0GQR1XS
UACC-893	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnTeoVKSzVyPUCuNVE5QDVizszN	Mon4V2FPT0WU
LU-65	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMUK2N\|Mh\|ryP	M4XQTHNCVkeHUh?=
HN	M4DKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMUOwO\|ch\|ryP	MXzTRW5ITVJ?
TI-73	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPFU4M6UUN3ME2wMlE1PzF3IN88US=>	Mlv1V2FPT0WU
KU812	NIO4[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMUW0OVYh\|ryP	M{Pad3NCVkeHUh?=
SW13	M4\mNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnlZYZYUUN3ME2wMlE3OjF4IN88US=>	NFTUfmtUSU6JRWK=
BB30-HNC	NFPsc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTwe4lTUUN3ME2wMlE3PTd4IN88US=>	MWXTRW5ITVJ?
HSC-2	M2LlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMU[4N\|ch\|ryP	MWLTRW5ITVJ?
BV-173	NEjQVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljkTWM2OD1yLkG3OVk3KM7:TR?=	MVLTRW5ITVJ?
CAL-27	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\aW5dHUUN3ME2wMlE4PjN4IN88US=>	MWTTRW5ITVJ?
SBC-1	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXXTotKSzVyPUCuNVg6PTlizszN	NIfaUFhUSU6JRWK=
CAL-33	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LVZ2lEPTB;MD6yNFE5PCEQvF2=	NVG3RlNrW0GQR1XS
NCI-H209	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfCTWM2OD1yLkKwOFYh\|ryP	Mn7QV2FPT0WU
COR-L105	NYHtcHhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT1TWM2OD1yLkKxNFg1KM7:TR?=	MmSxV2FPT0WU
HSC-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PaTWlEPTB;MD6yNVE6QCEQvF2=	M37zcnNCVkeHUh?=
NCI-H69	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nRcGlEPTB;MD6yNVQ2OSEQvF2=	M4H0Z3NCVkeHUh?=
MOLT-13	NI\XfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHQR5hvUUN3ME2wMlI{QTd3IN88US=>	MkLEV2FPT0WU
ML-2	M4fjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\STWM2OD1yLkK0PFAzKM7:TR?=	NHfuZVhUSU6JRWK=
IGROV-1	M3jQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfJU45KSzVyPUCuNlU6PTJizszN	M1fUdnNCVkeHUh?=
TK10	NYLURppbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3XT2VxUUN3ME2wMlI3PzN6IN88US=>	M2HPbXNCVkeHUh?=
EoL-1-cell	NFm0SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjxTWM2OD1yLkK2PFkzKM7:TR?=	Mnj4V2FPT0WU
HO-1-N-1	M3\kZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfPdopKSzVyPUCuNlc5PTNizszN	NYjHc\|BbW0GQR1XS
BHY	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMki2OVUh\|ryP	NV;UZ3ZNW0GQR1XS
LU-139	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwM{C1NUDPxE1?	NVvXRoV7W0GQR1XS
23132-87	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4iwXmlEPTB;MD6zNVkzOyEQvF2=	MlTkV2FPT0WU
ACHN	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7XU2g5UUN3ME2wMlMyQTl2IN88US=>	NGfkVHpUSU6JRWK=
DoTc2-4510	M162ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwM{KyNVkh\|ryP	M1fCR3NCVkeHUh?=
BB65-RCC	NGi4OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor2TWM2OD1yLkO0OVk{KM7:TR?=	NHnTWIRUSU6JRWK=
HLE	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;KTWM2OD1yLkO1NFQ3KM7:TR?=	NYXjS\|JZW0GQR1XS
HCC1419	M1T0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLPUXdKSzVyPUCuN\|Y1ODhizszN	MYPTRW5ITVJ?
A388	NVm3SpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHQTWM2OD1yLkO2PFU4KM7:TR?=	MYHTRW5ITVJ?
NUGC-3	NIr2e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwM{izO\|Mh\|ryP	NXr3RWY4W0GQR1XS
KYSE-180	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwM{mwPFkh\|ryP	MkHxV2FPT0WU
TE-6	M2HXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTNeYZSUUN3ME2wMlQxOjR4IN88US=>	MXnTRW5ITVJ?
A498	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe0WVlEUUN3ME2wMlQxPjd2IN88US=>	M2LTRXNCVkeHUh?=
NCI-H1648	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNESxPFIh\|ryP	NWHCWnFSW0GQR1XS
DU-145	NUnnWllST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPWTWM2OD1yLkS0PFM{KM7:TR?=	M{LYNHNCVkeHUh?=
CW-2	MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLoTWM2OD1yLkS2PVE1KM7:TR?=	M176[XNCVkeHUh?=
A431	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlW1TWM2OD1yLkS4NlM{KM7:TR?=	NF;GcVBUSU6JRWK=
SAS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfhTolKSzVyPUCuOFg{QThizszN	MmXPV2FPT0WU
NCI-H2126	NXTZU45bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm3XJRKSzVyPUCuOVE6OjZizszN	M4TGUXNCVkeHUh?=
NCI-H358	NYDCbmhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf6b5FKSzVyPUCuOVMzOSEQvF2=	NF7ReItUSU6JRWK=
FADU	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwNUS0NFQh\|ryP	M1fteXNCVkeHUh?=
ACN	NInFZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL3O5RLUUN3ME2wMlU2ODl2IN88US=>	NVvtfFhLW0GQR1XS
HCC70	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFu4Zm5KSzVyPUCuOVc3PjFizszN	MUnTRW5ITVJ?
NCI-H1838	NVzmb\|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj6T3JMUUN3ME2wMlYxOjl7IN88US=>	NG[xPWFUSU6JRWK=
CAL-54	M{nybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzqSo5mUUN3ME2wMlYyPjJzIN88US=>	MlnaV2FPT0WU
NCI-H1975	NIrGSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3RdoJKSzVyPUCuOlE4OjhizszN	NEPtWVVUSU6JRWK=
COR-L88	M3\KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPjUnVKSzVyPUCuOlQyOTNizszN	NVvRVlNYW0GQR1XS
CTV-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjpbmQzUUN3ME2wMlY1Ozl{IN88US=>	NWj3elc2W0GQR1XS
EW-18	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\mOHNUUUN3ME2wMlY5Pjl6IN88US=>	MnnSV2FPT0WU
HCC1806	M1O4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwNkm2OlYh\|ryP	NGDYe4pUSU6JRWK=
HuP-T4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnWXIlqUUN3ME2wMlY6PzZizszN	MnH6V2FPT0WU
MDA-MB-361	M{PIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn33TWM2OD1yLkeyOlYzKM7:TR?=	Mk[1V2FPT0WU
NCI-H1573	NEfIU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyxWnBKSzVyPUCuO\|M3OyEQvF2=	MnTCV2FPT0WU
KU-19-19	NEnFeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwN{e0OlQh\|ryP	M4XxWXNCVkeHUh?=
COLO-678	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXObYVKSzVyPUCuPFA5OzRizszN	NUK4Sm5IW0GQR1XS
C-33-A	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\6dYVKSzVyPUCuPFEzQTdizszN	MXrTRW5ITVJ?
Calu-3	NHjqdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v5N2lEPTB;MD64NVQ{PCEQvF2=	M{LabHNCVkeHUh?=
AGS	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTkS\|lKSzVyPUCuPFM3PDhizszN	M1TDTHNCVkeHUh?=
SCC-25	NHP3RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33WVGlEPTB;MD64OFE4OSEQvF2=	MV\TRW5ITVJ?
JVM-2	NV;MRZpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ezSGlEPTB;MD64PFI6QSEQvF2=	NVXqbmNYW0GQR1XS
HCE-T	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\jdmlEPTB;MD64PFQzQCEQvF2=	MYXTRW5ITVJ?
ES4	NYnOOWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3q5U2lEPTB;MD65O\|g{PiEQvF2=	MkXyV2FPT0WU
EKVX	NF7QR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrYenBKSzVyPUGuNFExPjRizszN	MULTRW5ITVJ?
D-542MG	NUHW[Y1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHtVZJwUUN3ME2xMlAyODZ2IN88US=>	MV;TRW5ITVJ?
SW1116	NUi2RmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPObGhoUUN3ME2xMlAyOjh5IN88US=>	MnTwV2FPT0WU
5637	NEfYN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[5c4NKSzVyPUGuNFE2OSEQvF2=	NVnKXoFVW0GQR1XS
HT-1376	NGqyb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFwMEG1NVMh\|ryP	MkTOV2FPT0WU
NB69	M2PzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrrTWM2OD1zLkCyPVQ2KM7:TR?=	MVzTRW5ITVJ?
YKG-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnXTWM2OD1zLkC1OFE6KM7:TR?=	NV\SclRUW0GQR1XS
EW-3	NYXrZlJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLNTWM2OD1zLkC3PFg{KM7:TR?=	MYPTRW5ITVJ?
GCIY	NXvGPI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH2dIpKSzVyPUGuNFgyODRizszN	MWXTRW5ITVJ?
SK-MES-1	Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DjWmlEPTB;MT6xNVQ5PyEQvF2=	MmfTV2FPT0WU
PANC-08-13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jxbGlEPTB;MT6xOlQyPiEQvF2=	NUPPc5RPW0GQR1XS
SK-NEP-1	M{TqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljYTWM2OD1zLkG3OVE{KM7:TR?=	NHvFbWZUSU6JRWK=
SW954	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfO[mR5UUN3ME2xMlIxOjF2IN88US=>	NWfLNYlqW0GQR1XS
NCI-SNU-5	M1HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPXXpl7UUN3ME2xMlI{QSEQvF2=	NVzzNnhoW0GQR1XS
SW48	NIH6W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFwMkW0N\|Ih\|ryP	MljEV2FPT0WU
HT-3	M33uWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXPTWM2OD1zLkK4O\|U{KM7:TR?=	NFTQWW1USU6JRWK=
ETK-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HpU2lEPTB;MT6zO\|Q2PiEQvF2=	MoXZV2FPT0WU
SCC-15	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrXNoJKSzVyPUGuN\|k1PTFizszN	NX6xdnZSW0GQR1XS
DU-4475	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnriTWM2OD1zLkSwNVIyKM7:TR?=	NF:4bHpUSU6JRWK=
NB5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPSbZdwUUN3ME2xMlQyOzF5IN88US=>	NWfzPFEzW0GQR1XS
CFPAC-1	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrSNIpKSzVyPUGuOFI1QTNizszN	NEG0OlBUSU6JRWK=
NCI-H630	NYDWfI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwNEW1PFIh\|ryP	NHHT[4xUSU6JRWK=
NCI-H82	NI\hRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon4TWM2OD1zLkW0NFA3KM7:TR?=	NXzESoJNW0GQR1XS
ECC10	NHr1eXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jBOWlEPTB;MT61OVM3QSEQvF2=	MmHTV2FPT0WU
K5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rEPGlEPTB;MT61PFM2PyEQvF2=	MVrTRW5ITVJ?
ME-180	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTFwNkGwPVYh\|ryP	MonlV2FPT0WU
KYSE-410	MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme5TWM2OD1zLk[1OlczKM7:TR?=	M{e0cXNCVkeHUh?=
G-401	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPQcldkUUN3ME2xMlY4PDF\|IN88US=>	NYfRPZE1W0GQR1XS
TGBC24TKB	NGH1WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPL[Y1tUUN3ME2xMlY5OjNizszN	M4GwVHNCVkeHUh?=
Detroit562	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Plc2lEPTB;MT63NFE2OiEQvF2=	NU\weI1yW0GQR1XS
OE19	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfETWM2OD1zLkexOVEzKM7:TR?=	NFXpTVlUSU6JRWK=
CAKI-1	NH3ac5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFwN{iyNVEh\|ryP	NGDSRmFUSU6JRWK=
TE-12	NXe4SpBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnOZ4lKSzVyPUGuPFA1OTRizszN	MVvTRW5ITVJ?
NCI-H1666	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwOEC5OFgh\|ryP	NFH5OFFUSU6JRWK=
TE-1	NGHKTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;lTGlEPTB;MT64NVQ4PSEQvF2=	MX3TRW5ITVJ?
CAL-12T	NW\kSZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn65TWM2OD1zLki4PVQ2KM7:TR?=	MYrTRW5ITVJ?
TE-8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnsTWM2OD1zLkmxN\|c4KM7:TR?=	MWfTRW5ITVJ?
KYSE-270	NVnaPXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTJwMEK3N\|Ih\|ryP	MWfTRW5ITVJ?
GMS-10	NEDwXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PmU2lEPTB;Mj6wN\|UyPyEQvF2=	M3LPNHNCVkeHUh?=
A2780	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTKTWM2OD1{LkC2Nlk1KM7:TR?=	NGjhPYtUSU6JRWK=
OMC-1	NWnKZXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rJTmlEPTB;Mj6wPFE3QSEQvF2=	MVvTRW5ITVJ?
LoVo	M1LzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJwMUC3PVch\|ryP	MXTTRW5ITVJ?
PANC-03-27	NWr0NJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v4U2lEPTB;Mj6xOlY{OSEQvF2=	MYLTRW5ITVJ?
MDA-MB-157	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrFfHF6UUN3ME2yMlIyQDJ6IN88US=>	MWXTRW5ITVJ?
CaR-1	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LNT2lEPTB;Mj6yPFI5OSEQvF2=	MXrTRW5ITVJ?
769-P	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfoTWM2OD1{LkK5NFM4KM7:TR?=	NYTpRZp7W0GQR1XS
NB7	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJwMkm2O\|Yh\|ryP	NHnLXVdUSU6JRWK=
MKN7	NXnse5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TtWGlEPTB;Mj6zOVM{PSEQvF2=	MVHTRW5ITVJ?
NCI-H1048	NWPhT4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlT3TWM2OD1{LkS5NVU5KM7:TR?=	M1yxRXNCVkeHUh?=
RCM-1	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jMcGlEPTB;Mj61Nlk{QCEQvF2=	MUXTRW5ITVJ?
HT55	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJwNUezPEDPxE1?	MXfTRW5ITVJ?
HCC1569	NV3XSWlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHBbpBmUUN3ME2yMlU5Ojl5IN88US=>	MX;TRW5ITVJ?
LXF-289	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH33TFBKSzVyPUKuOlM2PjVizszN	MWDTRW5ITVJ?
OVCAR-3	NHHCWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVryVpFbUUN3ME2yMlY4OTZ5IN88US=>	MYXTRW5ITVJ?
TE-10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITrfm9KSzVyPUKuOlgxPzhizszN	NFPSOGxUSU6JRWK=
SNU-C2B	NInYU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJwNki2NVYh\|ryP	NIq5SXNUSU6JRWK=
LB1047-RCC	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXqxR3BbUUN3ME2yMlc1QDh6IN88US=>	NHjpVllUSU6JRWK=
SN12C	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHOUHZKSzVyPUKuPVE6PjRizszN	MUDTRW5ITVJ?
786-0	NXntVJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn36TWM2OD1\|LkC2OFA5KM7:TR?=	MXLTRW5ITVJ?
HT-29	NUH6[FQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmThTWM2OD1\|LkC3N\|A6KM7:TR?=	NYHpR2tCW0GQR1XS
RPMI-7951	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jqbWlEPTB;Mz6wO\|U6KM7:TR?=	NXX0W4p5W0GQR1XS
NBsusSR	M3TtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zrVGlEPTB;Mz6xPFI2PCEQvF2=	M4PhR3NCVkeHUh?=
NKM-1	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPMTWM2OD1\|LkG4O\|Q1KM7:TR?=	NUfnc2JtW0GQR1XS
Capan-2	M1GwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\VTWM2OD1\|LkS2PFc2KM7:TR?=	MXnTRW5ITVJ?
MKN1	NHPEZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzYRZJKSzVyPUOuOFcyODhizszN	MYjTRW5ITVJ?
OAW-42	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3WybmlEPTB;Mz61NFAzPiEQvF2=	NFvZS21USU6JRWK=
SKG-IIIa	M{LWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\UNGlEPTB;Mz61NlI{PyEQvF2=	MnHJV2FPT0WU
no-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvs[ZB4UUN3ME2zMlU{PTZ2IN88US=>	M33rfnNCVkeHUh?=
NY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjPV4xFUUN3ME2zMlU{PjV3IN88US=>	MV3TRW5ITVJ?
HEC-1	NXTKd3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXvSpVrUUN3ME2zMlU5QTVizszN	MYLTRW5ITVJ?
NCI-H441	M3\1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\1cXFKSzVyPUOuOVk5PDFizszN	Mki0V2FPT0WU
NCI-H2009	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlruTWM2OD1\|Lk[xNlE3KM7:TR?=	M3nsfHNCVkeHUh?=
T47D	NWfpZ3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTNwNkKyNVch\|ryP	M{nlXnNCVkeHUh?=
SNU-449	NW\OWVByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrlU\|FKSzVyPUOuOlU5OjZizszN	NGLacmZUSU6JRWK=
NCI-SNU-1	NXvLe25vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\IfWlEPTB;Mz62PVc{PSEQvF2=	Mk\XV2FPT0WU
BT-20	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPGTWM2OD1\|Lk[5O\|k2KM7:TR?=	NV31RWtQW0GQR1XS
LS-123	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF2zO3FKSzVyPUOuO\|QzQDRizszN	M{\VdXNCVkeHUh?=
8305C	NYjLU444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTNwN{W5NVEh\|ryP	NYjiUYhGW0GQR1XS
OCUB-M	NFm4cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjzNWxEUUN3ME2zMlc3OTh5IN88US=>	MWjTRW5ITVJ?
KOSC-2	NFTzfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHjWJBEUUN3ME2zMlg{PDVzIN88US=>	MXXTRW5ITVJ?
NCI-H1693	NGXUe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M325XWlEPTB;Mz64OFE5OSEQvF2=	MXTTRW5ITVJ?
TE-9	NYrMS\|luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LkUWlEPTB;Mz64OFM5OiEQvF2=	NUTacHNuW0GQR1XS
MV-4-11	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPYRnhKSzVyPUOuPFc6QTRizszN	NF3kUGZUSU6JRWK=
GAMG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH76TZBKSzVyPUOuPVE{OTRizszN	NVXJcG9sW0GQR1XS
KNS-62	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3NO4lKSzVyPUOuPVQ4OzFizszN	NYK5fXdKW0GQR1XS
MC116	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjITWM2OD1\|Lkm1OFg6KM7:TR?=	M4nteHNCVkeHUh?=
647-V	M1;yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHCTWM2OD1\|Lkm4OFUzKM7:TR?=	MVPTRW5ITVJ?
U-87-MG	NHS0VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17PZmlEPTB;ND6xNFQ5OSEQvF2=	NXvGRYZkW0GQR1XS
RPMI-8226	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlG2TWM2OD12LkGxOlMyKM7:TR?=	NEnvOVZUSU6JRWK=
SW1417	NX;Rb5gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLLTWM2OD12LkGyNVQ4KM7:TR?=	MlGyV2FPT0WU
LAMA-84	NHnNOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\2S3RKSzVyPUSuNVcxOiEQvF2=	NWLRdZJkW0GQR1XS
LS-513	M3\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\oTWM2OD12LkOxNlE4KM7:TR?=	MVPTRW5ITVJ?
KLE	M3fJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1qyO2lEPTB;ND60NFgyQSEQvF2=	NXiwRmdlW0GQR1XS
HCT-116	NFSwVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzHXlZxUUN3ME20MlQyODB5IN88US=>	MYjTRW5ITVJ?
EPLC-272H	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i3ZWlEPTB;ND60NVU{OyEQvF2=	MXHTRW5ITVJ?
KS-1	NH3GOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjJVWpKSzVyPUSuOVA5QDlizszN	M3npTXNCVkeHUh?=
HT-1197	NXXyN3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HvXWlEPTB;ND61NlY3QSEQvF2=	M3jNTXNCVkeHUh?=
LCLC-97TM1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fBVmlEPTB;ND61N\|Y5PiEQvF2=	MVTTRW5ITVJ?
ES5	NUTnOWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nhfmlEPTB;ND64N\|czOyEQvF2=	MYHTRW5ITVJ?
CTB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzZRWVjUUN3ME20Mlg1QDhizszN	NY\rR2Q4W0GQR1XS
HL-60	NFXTVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTRwOE[2NVEh\|ryP	MnjTV2FPT0WU
VM-CUB-1	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTXTWM2OD12Lki2PFE6KM7:TR?=	MYTTRW5ITVJ?
MEG-01	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfzZWJKSzVyPUSuPVk1ODNizszN	NVPsSYI6W0GQR1XS
KYSE-520	NVW3d2NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTVwMkC4N\|kh\|ryP	M4e4fnNCVkeHUh?=
HuO-3N1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TLW2lEPTB;NT6yOFA1OyEQvF2=	Ml;uV2FPT0WU
SW620	Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTVwMkS5OlQh\|ryP	NVe2R24zW0GQR1XS
U031	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HKTmlEPTB;NT6yOVQzPCEQvF2=	MkTqV2FPT0WU
TE-5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTBTWM2OD13LkSwPFUh\|ryP	MWHTRW5ITVJ?
NCI-H747	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\xcWlEPTB;NT60NlQ4OiEQvF2=	NESyO5BUSU6JRWK=
MG-63	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PDcGlEPTB;NT60PFc3OiEQvF2=	M4e4TnNCVkeHUh?=
HC-1	NEizOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTVwNUG4N\|kh\|ryP	MUHTRW5ITVJ?
HCC2998	M4TXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\kTWM2OD13LkWyOlE2KM7:TR?=	MnTYV2FPT0WU
NTERA-S-cl-D1	M3rTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3icW5KSzVyPUWuOVQ2OzdizszN	M1fCNnNCVkeHUh?=
KINGS-1	NIPSTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTVwNkC5OFQh\|ryP	MYTTRW5ITVJ?
D-423MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LoZmlEPTB;NT62NVcxPSEQvF2=	MVzTRW5ITVJ?
SW962	NUPpdXhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHEd5pKSzVyPUWuOlIxOzJizszN	NIHH[Y9USU6JRWK=
LOXIMVI	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHscYRYUUN3ME21MlY{QDd\|IN88US=>	NV\idJdPW0GQR1XS
LS-411N	NIr1V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTVwN{m0OFEh\|ryP	M1nNSHNCVkeHUh?=
NCI-H2291	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjYXVNKSzVyPUWuPVg6PDNizszN	M1;IVnNCVkeHUh?=
A549	NIDpW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf3NHpKSzVyPU[uNVI2PTNizszN	M{\kNnNCVkeHUh?=
LS-1034	M2nDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvFVXRKSzVyPU[uNlA4ODZizszN	MlTQV2FPT0WU
NB14	M2fOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTZwNEO4N\|Yh\|ryP	NX74cnZFW0GQR1XS
NCI-H1299	NHuwNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jHWmlEPTB;Nj62N\|E4OSEQvF2=	MWHTRW5ITVJ?
BT-549	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nxcGlEPTB;Nj62Olg5QSEQvF2=	MX3TRW5ITVJ?
J-RT3-T3-5	NEDOTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTZwOE[5JO69VQ>?	MXvTRW5ITVJ?
SW756	NImydFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O2TWlEPTB;Nj65NVE4PiEQvF2=	NHu0OJRUSU6JRWK=
DJM-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrGTWM2OD14LkmyNFEzKM7:TR?=	Ml;tV2FPT0WU
GP5d	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Oyb2lEPTB;Nj65O\|M6PCEQvF2=	MVrTRW5ITVJ?
MOLT-4	NHq0do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nKXWlEPTB;Nz6wNlE{PSEQvF2=	MV3TRW5ITVJ?
NCI-H28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTdwMU[0NFUh\|ryP	MYLTRW5ITVJ?
MN-60	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHyT\|BKSzVyPUeuNlgxQDlizszN	M2HIdXNCVkeHUh?=
RMG-I	NX\OVGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXTOFdmUUN3ME23MlM6Ojl4IN88US=>	NHvYN3NUSU6JRWK=
COLO-800	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXNcY9QUUN3ME23MlQyPDR4IN88US=>	MXjTRW5ITVJ?
DB	NX3ZUm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rsV2lEPTB;Nz62NVAxPSEQvF2=	MnriV2FPT0WU
Ca-Ski	NXvhbHNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DsV2lEPTB;Nz62OFI2QSEQvF2=	MY\TRW5ITVJ?
HEL	NUCzUpJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXjT\|ZKSzVyPUeuO\|EzODNizszN	MmLpV2FPT0WU
NH-12	NVPVdnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELNdGhKSzVyPUeuO\|I5ODhizszN	NEnNeIRUSU6JRWK=
LB373-MEL-D	NXToWZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTdwN{[3O\|Eh\|ryP	M3KwUnNCVkeHUh?=
SW900	NFTIN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\1Z2lEPTB;Nz64NlEzOSEQvF2=	NG\BS5hUSU6JRWK=
JVM-3	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\MSYxKSzVyPUeuPFk2QTlizszN	NUXIeHFFW0GQR1XS
OAW-28	NF7aNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu1fJpKSzVyPUeuPVQ2PzhizszN	NXj0[FZNW0GQR1XS
KURAMOCHI	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfBO3N2UUN3ME23Mlk1QDFzIN88US=>	NI\P[3pUSU6JRWK=
BE-13	NY\i[FVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nOcGlEPTB;Nz65PFEyOiEQvF2=	NWDXTpVjW0GQR1XS
VMRC-RCZ	NFHj[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRThwMEG2PVch\|ryP	M4jBZXNCVkeHUh?=
NCI-H727	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PvWWlEPTB;OD6xNFQzKM7:TR?=	NX;IcHpUW0GQR1XS
SW1710	NELtT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrZTWM2OD16LkG4OVE2KM7:TR?=	MUjTRW5ITVJ?
D-502MG	NGLvRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRThwMkmyPFIh\|ryP	NWnxbJZ[W0GQR1XS
NCI-H1993	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OwPGlEPTB;OD6zN\|Y{OSEQvF2=	NYjNb2Z1W0GQR1XS
SCC-4	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHZcmV5UUN3ME24MlQ1ODV7IN88US=>	NELidZRUSU6JRWK=
HAL-01	NVftZ3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRThwNUG5NUDPxE1?	MnLEV2FPT0WU
GT3TKB	NWW5No84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G1fmlEPTB;OD62O\|k3PCEQvF2=	MV\TRW5ITVJ?
SK-OV-3	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17hdWlEPTB;OD63NVMzQSEQvF2=	M1W4O3NCVkeHUh?=
COLO-829	NHSyepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K5OmlEPTB;OD64NFk4PiEQvF2=	M3;YUnNCVkeHUh?=
OCI-AML2	M3SzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLnSlFKSzVyPUiuPVU1QDFizszN	NYLMXohpW0GQR1XS
OS-RC-2	NEPZSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHH4SXdKSzVyPUmuNFIyQSEQvF2=	NGDXdm5USU6JRWK=
BFTC-909	M1frUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEK1[HFKSzVyPUmuNFY4QTlizszN	NV\3UWNMW0GQR1XS
EW-11	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HjRWlEPTB;OT6xO\|Y2OyEQvF2=	MUXTRW5ITVJ?
HCE-4	NVrudWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPIclZKSzVyPUmuNlE2PThizszN	NXPNZmpkW0GQR1XS
BALL-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe4O\|VPUUN3ME25MlIyQTB5IN88US=>	MoPLV2FPT0WU
SF539	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[3OWlEPTB;OT6yN\|U3OiEQvF2=	NI\xdIpUSU6JRWK=
CAMA-1	NH7U[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m5[WlEPTB;OT6yPFEzQCEQvF2=	M3HJT3NCVkeHUh?=
C32	NFrpNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFi5THlKSzVyPUmuN\|MxPjRizszN	MXjTRW5ITVJ?
NCI-H1703	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfyTWM2OD17LkO0N\|c2KM7:TR?=	MUPTRW5ITVJ?
NCI-H1650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HCRmlEPTB;OT62NFk1PiEQvF2=	M1TVSHNCVkeHUh?=
NCI-H1563	M{Lid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z0cWlEPTB;OT63OlA{OSEQvF2=	NXTafppXW0GQR1XS
CAL-85-1	M{T1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXqTWM2OD17Lki3N\|g{KM7:TR?=	MoXZV2FPT0WU
UM-UC-3	M4CybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mne4TWM2OD17Lkm1NFMh\|ryP	NXzGZ\|JHW0GQR1XS
BxPC-3	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTFyLkC5O\|Ih\|ryP	Mn7NV2FPT0WU
MHH-PREB-1	M3HF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFyLkG5PVkh\|ryP	NIPBS\|BUSU6JRWK=
DEL	NH7EUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrBc2dKSzVyPUGwMlM6PDZizszN	M3XVPXNCVkeHUh?=
HuCCT1	NEfk[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFyLk[wN\|Mh\|ryP	MXrTRW5ITVJ?
OVCAR-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjpTWM2OD1zMD64PFM2KM7:TR?=	NYGx[Yl{W0GQR1XS
CAL-72	NW\zcpZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vQNWlEPTB;MUCuPVM6OSEQvF2=	NH7JUlBUSU6JRWK=
HCC1954	NXLERmxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFzLkC3OVQh\|ryP	MmHPV2FPT0WU
EFO-21	NYjZb\|k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGmzZmtKSzVyPUGxMlExPDVizszN	NVfUN2t{W0GQR1XS
FTC-133	NGry[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HhN2lEPTB;MUGuNVQxPyEQvF2=	MnnZV2FPT0WU
SK-MEL-24	NEnrNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn1cnVKSzVyPUGxMlI{PjZizszN	MkXuV2FPT0WU
UACC-62	NXrXO3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vPb2lEPTB;MUGuNlM3QCEQvF2=	NXzSfGZkW0GQR1XS
NCI-H650	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7ST2ZVUUN3ME2xNU4zPDF6IN88US=>	NIfCbZFUSU6JRWK=
ALL-PO	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HHT2lEPTB;MUGuNlUyOiEQvF2=	NXfiV21MW0GQR1XS
T84	NH\lZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljsTWM2OD1zMT6zPVA4KM7:TR?=	NE\EVGlUSU6JRWK=
IST-MEL1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DueWlEPTB;MUGuOFU2QSEQvF2=	NXXEVpljW0GQR1XS
SW626	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fTOGlEPTB;MUGuOVc2PSEQvF2=	MoL1V2FPT0WU
RPMI-2650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTEelQzUUN3ME2xNU42QDh3IN88US=>	MYjTRW5ITVJ?
MC-IXC	NX;MOI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Pwd2lEPTB;MUGuOlczQCEQvF2=	M{n2dXNCVkeHUh?=
HOP-62	NHHqUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rDTGlEPTB;MUGuOlc3PCEQvF2=	MmPoV2FPT0WU
NOS-1	M4DrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\1S2lEPTB;MUGuO\|ExQSEQvF2=	NEDtXWxUSU6JRWK=
SW1573	NHTIe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFzLkeyPVUh\|ryP	Mo\KV2FPT0WU
WM-115	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELEZoJKSzVyPUGxMlc2QDhizszN	MmfiV2FPT0WU
HuO9	M3\NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrnTWM2OD1zMT64O\|c1KM7:TR?=	M{DlWHNCVkeHUh?=
YAPC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDwTWM2OD1zMT65NlU6KM7:TR?=	MYnTRW5ITVJ?
MDA-MB-453	M3PVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHj0PFFKSzVyPUGxMlk2OTVizszN	MnryV2FPT0WU
NCI-H596	NUTGV3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF{LkCzOlkh\|ryP	M4\JVHNCVkeHUh?=
A172	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXjfY1iUUN3ME2xNk4xPzl6IN88US=>	MorpV2FPT0WU
RS4-11	M12yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHzTWM2OD1zMj6xO\|I2KM7:TR?=	MlH0V2FPT0WU
HCC1937	NGjQdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf1d\|VQUUN3ME2xNk44PTZ2IN88US=>	MlzXV2FPT0WU
SW837	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF{LkmwNlgh\|ryP	NXrZPJA2W0GQR1XS
NMC-G1	NE\QRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF{LkmyN\|Qh\|ryP	NHHkVmRUSU6JRWK=
PFSK-1	NXOz[os5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:5O2lEPTB;MUOuNFYh\|ryP	Ml\jV2FPT0WU
DBTRG-05MG	M2naPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfoT3ZHUUN3ME2xN{4xPjN{IN88US=>	Ml\3V2FPT0WU
SK-UT-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TOfmlEPTB;MUOuNVA5OyEQvF2=	MkfiV2FPT0WU
OVCAR-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTw[3lVUUN3ME2xN{4yPTl\|IN88US=>	MkfSV2FPT0WU
8505C	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTF\|LkKwOlch\|ryP	M1;3OHNCVkeHUh?=
SK-MEL-1	NF;TXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn6RppNUUN3ME2xN{44OTN3IN88US=>	MXTTRW5ITVJ?
LK-2	NX\4[3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF\|Lke2N\|kh\|ryP	MUnTRW5ITVJ?
OE33	NUny[I5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTF\|Lke4OkDPxE1?	NVy2UnNrW0GQR1XS
Ramos-2G6-4C10	M3W5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PtWGlEPTB;MUSuNFIxOiEQvF2=	NFy2WXdUSU6JRWK=
EW-13	M1HjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTFTWM2OD1zND6wN\|UzKM7:TR?=	NX3ObFVlW0GQR1XS
NCI-H1793	NVfWdZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTF2LkKwPFch\|ryP	M{jiXHNCVkeHUh?=
BHT-101	NGDwZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPITWM2OD1zND6yOFEh\|ryP	M3LVV3NCVkeHUh?=
RKO	NVrNdml2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Xhd2lEPTB;MUSuOVA4PSEQvF2=	MUHTRW5ITVJ?
NEC8	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrlTWM2OD1zND61OFczKM7:TR?=	NXXlXG9RW0GQR1XS
PANC-10-05	M3PMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTF2Lk[yOFch\|ryP	MYDTRW5ITVJ?
NCI-H2030	NWTqeYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rqRWlEPTB;MUSuOlQ1QCEQvF2=	NXrjPVNJW0GQR1XS
C2BBe1	NFywcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTF2Lke2OEDPxE1?	M2noTHNCVkeHUh?=
EM-2	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF2Lki1O\|Yh\|ryP	NHr4NXBUSU6JRWK=
HCC1395	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C3TmlEPTB;MUSuPVM{QCEQvF2=	M{XJS3NCVkeHUh?=
A2058	M1S4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPoTWM2OD1zNT6wOFA6KM7:TR?=	MkTBV2FPT0WU
SW1463	M4jQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXTPZB2UUN3ME2xOU4xPDh3IN88US=>	NFuz[4hUSU6JRWK=
J82	NXPuO5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TkNWlEPTB;MUWuNFU4KM7:TR?=	M1rIe3NCVkeHUh?=
CAL-120	NYi1VoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTF3LkG0OFch\|ryP	NWC5VnZtW0GQR1XS
COLO-824	NXzF[4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HlNmlEPTB;MUWuNVU4QSEQvF2=	M3nYdHNCVkeHUh?=
LNCaP-Clone-FGC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHi2dHJKSzVyPUG1MlQzPDhizszN	NW\Te2FFW0GQR1XS
CP66-MEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TuZ2lEPTB;MUWuOFY5QCEQvF2=	MVPTRW5ITVJ?
OC-314	NH3yOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfEW2RKSzVyPUG1MlQ4OTRizszN	M4DLNXNCVkeHUh?=
OVCAR-8	M4PpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\0bJFKSzVyPUG1Mlg5PjFizszN	NVPwVIM6W0GQR1XS
MFE-280	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;hTWM2OD1zNj6wOFg5KM7:TR?=	M2f5O3NCVkeHUh?=
MHH-NB-11	NY[3OFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;BdWlEPTB;MU[uNFg{QSEQvF2=	MX;TRW5ITVJ?
SW1990	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDSRm9DUUN3ME2xOk4yPzV3IN88US=>	NIWwblhUSU6JRWK=
U-266	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\nUoFPUUN3ME2xOk4zOjl7IN88US=>	MWrTRW5ITVJ?
MFM-223	NEK0PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;2R2lEPTB;MU[uN\|k3PSEQvF2=	Ml7vV2FPT0WU
L-363	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTF4LkS1O\|ch\|ryP	NWToWIZIW0GQR1XS
MCF7	M1XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDvflByUUN3ME2xOk41PzJ\|IN88US=>	NX\nNWY2W0GQR1XS
SK-MEL-3	NYHWW\|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7vb3pUUUN3ME2xOk41Pzh5IN88US=>	M3XWeXNCVkeHUh?=
HH	NEixUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnoTWM2OD1zNj61NVYzKM7:TR?=	MnjJV2FPT0WU
no-10	NWPOfI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD4e\|ZqUUN3ME2xOk43OzR\|IN88US=>	MoLLV2FPT0WU
HuP-T3	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHyTWM2OD1zNj62OVc3KM7:TR?=	M3\BVXNCVkeHUh?=
QIMR-WIL	NYjMWWFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjqPIlKSzVyPUG2MlcyODVizszN	M{XTNXNCVkeHUh?=
NCI-H1092	NH3kO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPTS\|hHUUN3ME2xOk45OzF4IN88US=>	MXXTRW5ITVJ?
MZ2-MEL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELDSIxKSzVyPUG2Mlg1ODNizszN	NWDyTm5PW0GQR1XS
ES3	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTF4LkmxN\|Qh\|ryP	M4KxeHNCVkeHUh?=
COLO-684	M1yxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHu[VhKSzVyPUG2Mlk1PzdizszN	MVTTRW5ITVJ?
NCI-H661	M{L1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jsWGlEPTB;MU[uPVY6PCEQvF2=	NWK5bJdqW0GQR1XS
CP50-MEL-B	NUP1VFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HUV2lEPTB;MUeuNFM1OyEQvF2=	NEm2T5JUSU6JRWK=
NCI-H2405	NE\qRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHEZ\|BwUUN3ME2xO{4yQTd2IN88US=>	MVnTRW5ITVJ?
U-2-OS	NWDJOJhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[wTWlEPTB;MUeuOVMxPyEQvF2=	Mn7aV2FPT0WU
RERF-LC-MS	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF5LkW1NFgh\|ryP	Mn\3V2FPT0WU
NCI-H2342	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7ZTWM2OD1zNz61OVch\|ryP	MlHiV2FPT0WU
ES8	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTF5Lk[wPFch\|ryP	MWnTRW5ITVJ?
MOLT-16	NXrVOFJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHO1XpVKSzVyPUG3Mlg6OzRizszN	NILZVItUSU6JRWK=
RH-18	NI\6cHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLoTWM2OD1zOD6wNFM2KM7:TR?=	NF3Q[GVUSU6JRWK=
D-283MED	NXi2SWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e4dmlEPTB;MUiuNFA5QCEQvF2=	NG\uT3lUSU6JRWK=
RCC10RGB	NYHyWpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli1TWM2OD1zOD6wOVU6KM7:TR?=	MUTTRW5ITVJ?
NCI-H1437	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW2TWM2OD1zOD6xOlQyKM7:TR?=	M{m2RXNCVkeHUh?=
SW982	NV;Ue2IzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGntbVZKSzVyPUG4MlI3PzFizszN	NFjZWXNUSU6JRWK=
IST-MES1	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfNbFFiUUN3ME2xPE41PDJ6IN88US=>	NGP1TWpUSU6JRWK=
A704	NFnN[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTF6LkS3OVMh\|ryP	NWX1[GJUW0GQR1XS
ESS-1	M3vqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXx[VFKSzVyPUG4MlUzODVizszN	MULTRW5ITVJ?
SCH	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX4OHdKSzVyPUG4MlY1PTZizszN	NVToNGo4W0GQR1XS
COLO-320-HSR	NFv0N5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{SxT2lEPTB;MUiuO\|Q3KM7:TR?=	MmDQV2FPT0WU
Mo-T	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLqd3o4UUN3ME2xPE45OjB2IN88US=>	M2T1W3NCVkeHUh?=
Saos-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF7LkGxOlIh\|ryP	MYrTRW5ITVJ?
SW684	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X1VmlEPTB;MUmuNVMzPiEQvF2=	NHLQXGlUSU6JRWK=
KMOE-2	NUX5SIpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zlXGlEPTB;MUmuNlI1OiEQvF2=	MofMV2FPT0WU
MMAC-SF	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPROZlKSzVyPUG5MlI3ODdizszN	Ml\0V2FPT0WU
JAR	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfZZ3ZKSzVyPUG5MlI6QSEQvF2=	NWH6dmk3W0GQR1XS
SK-MEL-28	NGHzfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXrOYFSUUN3ME2xPU4{OzZ\|IN88US=>	NHrMflBUSU6JRWK=
KNS-81-FD	M{\jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmSzTWM2OD1zOT61OFY5KM7:TR?=	MmK1V2FPT0WU
ES7	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrZTWM2OD1zOT62NlkzKM7:TR?=	NXry[nZ[W0GQR1XS
AsPC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[0UmZJUUN3ME2xPU43PDdzIN88US=>	M{f2WXNCVkeHUh?=
NCI-H1155	NYHWT5pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXhZpRKSzVyPUG5MlczOzhizszN	M3ThXnNCVkeHUh?=
KYSE-510	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTNbIhTUUN3ME2xPU45PzR6IN88US=>	MWDTRW5ITVJ?
ES1	M3i5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXKTWM2OD1zOT65NlE{KM7:TR?=	MY\TRW5ITVJ?
PC-3	NVTw[5BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PGNWlEPTB;MUmuPVYxPCEQvF2=	M2ez[nNCVkeHUh?=
GCT	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXsTWM2OD1{MD6zNFI3KM7:TR?=	MkeyV2FPT0WU
KARPAS-299	NH\IO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrWWmFKSzVyPUKwMlM1OjJizszN	NUfuUm9YW0GQR1XS
DOHH-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr2Oo4xUUN3ME2yNE42PDZ\|IN88US=>	MWrTRW5ITVJ?
COLO-741	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHS[pRKSzVyPUKwMlY3KM7:TR?=	MWTTRW5ITVJ?
NCI-H1395	NYH1XIlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXrTWM2OD1{MD62Olk4KM7:TR?=	NXjJOHVkW0GQR1XS
HCC1187	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;WfmZKSzVyPUKwMlY4OzRizszN	MUHTRW5ITVJ?
Becker	NFztPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJyLkeyNFEh\|ryP	NX;YW5J3W0GQR1XS
LU-134-A	NW\zT5hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX0WZd2UUN3ME2yNU4yODJ4IN88US=>	MUHTRW5ITVJ?
MKN45	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DycmlEPTB;MkGuNVU2OSEQvF2=	M2riO3NCVkeHUh?=
LC-2-ad	NF7ScFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\pSXFyUUN3ME2yNU4zPzJ7IN88US=>	MUPTRW5ITVJ?
EW-24	M4DH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJzLkO5OFUh\|ryP	MVfTRW5ITVJ?
SK-N-AS	NH3qR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTJzLkiyO\|Yh\|ryP	Mor0V2FPT0WU
NCI-H2052	M3jDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\XTWM2OD1{MT64PVY{KM7:TR?=	MlLLV2FPT0WU
A4-Fuk	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHCPZlKSzVyPUKyMlE1OTlizszN	MVfTRW5ITVJ?
NB10	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHETWM2OD1{Mj6yN\|cyKM7:TR?=	MmLxV2FPT0WU
CHP-212	NFnHfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ{LkOyNlIh\|ryP	MW\TRW5ITVJ?
KM12	M{j6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\oTWM2OD1{Mj6zOVYh\|ryP	M3nQSXNCVkeHUh?=
JEG-3	M4LvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLqOoFKSzVyPUKyMlM4QCEQvF2=	M1:yWXNCVkeHUh?=
LN-405	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jqc2lEPTB;MkKuOVkyOyEQvF2=	Moj4V2FPT0WU
HCT-15	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX60foNqUUN3ME2yNk44PDRzIN88US=>	NH7HcJNUSU6JRWK=
MLMA	Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HRUGlEPTB;MkKuO\|Q4KM7:TR?=	MWrTRW5ITVJ?
GI-1	M37scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXJTFZmUUN3ME2yNk44PjV6IN88US=>	NIPnWGxUSU6JRWK=
RT-112	M1nFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTJ{Lki2NVYh\|ryP	M{DCeHNCVkeHUh?=
MPP-89	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTJ{Lki2OlEh\|ryP	M3zqfXNCVkeHUh?=
A3-KAW	M1vEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPnU5F2UUN3ME2yN{4yODB\|IN88US=>	MkLYV2FPT0WU
KALS-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvtdGlKSzVyPUKzMlE1OTRizszN	NV[0Zox1W0GQR1XS
SF126	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVziNZdqUUN3ME2yN{43QTJ2IN88US=>	MWrTRW5ITVJ?
SiHa	NHTIWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DmWmlEPTB;MkOuPVMzPyEQvF2=	NIe0OVJUSU6JRWK=
MDA-MB-415	NW\meoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHYU2o{UUN3ME2yN{46PDl7IN88US=>	MULTRW5ITVJ?
Daoy	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDNe2VKSzVyPUK0MlEzPiEQvF2=	Ml3qV2FPT0WU
COR-L23	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37nNWlEPTB;MkSuNVc3PyEQvF2=	NEfxT\|lUSU6JRWK=
KG-1	M2LMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\mUoVvUUN3ME2yOE4yQTJ6IN88US=>	M4\WWnNCVkeHUh?=
L-428	M3HhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTlOGJKSzVyPUK0MlU4QTFizszN	MlftV2FPT0WU
NCI-H520	NFP5fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTJ2Lki4OlEh\|ryP	NF;U[3dUSU6JRWK=
COLO-792	NUXtSmllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLRTWM2OD1{NT6yO\|MzKM7:TR?=	MkWyV2FPT0WU
NB12	NUTJeJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r5e2lEPTB;MkWuNlk1PyEQvF2=	NIjKfYVUSU6JRWK=
GAK	NYG0fFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDKXINuUUN3ME2yOU4zQTZ\|IN88US=>	MXzTRW5ITVJ?
SW780	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELKTnhKSzVyPUK1MlMzPjRizszN	M37qPHNCVkeHUh?=
GB-1	NGC3VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLJdZBKSzVyPUK1MlQxPjlizszN	NWH4dIVsW0GQR1XS
P12-ICHIKAWA	NVm4W5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLO[YtKSzVyPUK1MlQ4QDVizszN	MUXTRW5ITVJ?
NCI-H1651	M3;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ3LkW5O{DPxE1?	NYHZWINzW0GQR1XS
KE-37	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LDN2lEPTB;MkWuO\|MyPSEQvF2=	MmjyV2FPT0WU
CCRF-CEM	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFmw[pRKSzVyPUK1Mlk3PyEQvF2=	MYnTRW5ITVJ?
SF295	NHrR[\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPafXl{UUN3ME2yOk4xPDJ3IN88US=>	MmPDV2FPT0WU
G-361	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDJTWM2OD1{Nj6xNFI4KM7:TR?=	MYTTRW5ITVJ?
HOP-92	M{TmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDTTWM2OD1{Nj6xNlI3KM7:TR?=	NYPWZ215W0GQR1XS
UMC-11	NVTreWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDMbXZKSzVyPUK2MlQ2OTRizszN	NGrpW3hUSU6JRWK=
IST-SL1	NUCzXIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXPV4pKSzVyPUK2MlY2QTFizszN	M3z0bHNCVkeHUh?=
TE-11	NXjIXW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TMXWlEPTB;Mk[uO\|c2OiEQvF2=	NX64R4FtW0GQR1XS
NCI-H1304	NVnRUmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTJ4LkmxNFgh\|ryP	NYXh[5FoW0GQR1XS
SJSA-1	M3;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTJ5LkCxO\|Yh\|ryP	MnHWV2FPT0WU
BCPAP	NIj6dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LobGlEPTB;MkeuNVM4KM7:TR?=	NXfON4RDW0GQR1XS
HTC-C3	NHH3[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTweHRYUUN3ME2yO{4zPTZzIN88US=>	Mn30V2FPT0WU
EW-16	M1L6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJ5LkK5OFch\|ryP	MnfmV2FPT0WU
HT-144	NVjCcZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfLV4VSUUN3ME2yO{41ODN{IN88US=>	NXL6bWFyW0GQR1XS
MHH-ES-1	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XSXGlEPTB;MkeuOFQ1PyEQvF2=	NIjVZ4hUSU6JRWK=
T98G	MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJ5LkW4OFYh\|ryP	NIfmcYVUSU6JRWK=
RPMI-8866	M1fWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTJ5Lke1OlIh\|ryP	M2G0T3NCVkeHUh?=
BEN	M4Tqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\5TWM2OD1{Nz64OVE4KM7:TR?=	MoDVV2FPT0WU
MDA-MB-231	NFHyS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hmc2lEPTB;MkiuNlc6PSEQvF2=	Ml;iV2FPT0WU
HuH-7	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOzTWM2OD1{OD60NFI5KM7:TR?=	MofPV2FPT0WU
SK-N-FI	NH3xWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXRNmNCUUN3ME2yPE41OzNizszN	M1\3XXNCVkeHUh?=
AN3-CA	M1zFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTaSlc2UUN3ME2yPE41Ozl3IN88US=>	MmfIV2FPT0WU
EGI-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJ6LkW5Nlgh\|ryP	NWHQXnJXW0GQR1XS
697	M2fDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTJ6Lk[zN\|Eh\|ryP	MmDEV2FPT0WU
TCCSUP	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTTOVZCUUN3ME2yPE43PDF6IN88US=>	MoT4V2FPT0WU
GR-ST	NWCzVnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHTTWM2OD1{OD62Olk3KM7:TR?=	M2rSUXNCVkeHUh?=
SK-N-DZ	M2W2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJ6Lk[4PFUh\|ryP	MVnTRW5ITVJ?
MIA-PaCa-2	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUH2[JpFUUN3ME2yPE44QTV7IN88US=>	MXnTRW5ITVJ?
IGR-1	M4HoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv0dVJKUUN3ME2yPE45QDd2IN88US=>	NVrqWXlSW0GQR1XS
BFTC-905	NHTqXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3qz[2lEPTB;MkmuNlcxPSEQvF2=	Mnm4V2FPT0WU
NCI-H1581	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzz[Y9IUUN3ME2yPU4{OTR3IN88US=>	Mn7tV2FPT0WU
RD	M{jCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rS[WlEPTB;MkmuOVI{OyEQvF2=	M2e2WXNCVkeHUh?=
SF268	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrrTWM2OD1{OT61PVMyKM7:TR?=	NYTteYdVW0GQR1XS
SHP-77	NFixeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL3bI5sUUN3ME2yPU43OTh{IN88US=>	M3nNVnNCVkeHUh?=
D-566MG	NUDQd3pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD2TWM2OD1{OT65N\|k{KM7:TR?=	Mo\5V2FPT0WU
TGBC1TKB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTNyLkGyN\|gh\|ryP	M4jvOnNCVkeHUh?=
MEL-HO	M{fyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3qyN2lEPTB;M{CuNVQzOyEQvF2=	MlzEV2FPT0WU
SJRH30	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nRPWlEPTB;M{CuNlExQCEQvF2=	MlPFV2FPT0WU
D-336MG	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2X5fWlEPTB;M{CuNlg6OiEQvF2=	MlfPV2FPT0WU
C3A	NWfXbGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnhT3lXUUN3ME2zNE4zQTJ5IN88US=>	NEPZUpZUSU6JRWK=
Calu-6	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HjeWlEPTB;M{CuNlk3OyEQvF2=	MoTIV2FPT0WU
MZ1-PC	MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzhdGtKSzVyPUOwMlM6OyEQvF2=	MWHTRW5ITVJ?
KYSE-70	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXPb2dKSzVyPUOwMlUyOTRizszN	MkHtV2FPT0WU
CAPAN-1	M33C[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvoTWM2OD1\|MD61NVgyKM7:TR?=	NVrIUoZjW0GQR1XS
DK-MG	NHT2cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4K2bmlEPTB;M{CuOVQ2PiEQvF2=	NVT4Zow3W0GQR1XS
SK-HEP-1	MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjHTWM2OD1\|MD62N\|I3KM7:TR?=	NW[xPXN2W0GQR1XS
MS-1	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDifoV6UUN3ME2zNE45QDh7IN88US=>	MX3TRW5ITVJ?
GI-ME-N	NFj4PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\zdYlKSzVyPUOxMlA2PzFizszN	MnGxV2FPT0WU
NCI-H510A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTNzLkSwNFYh\|ryP	NUjKb2R[W0GQR1XS
NB17	NH24RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHCTWM2OD1\|MT61NVg2KM7:TR?=	NFjRRphUSU6JRWK=
639-V	M2rRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT6fpNIUUN3ME2zNU42OjR\|IN88US=>	NHPFcHlUSU6JRWK=
CAL-51	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;tTWM2OD1\|MT61OlY4KM7:TR?=	M163NXNCVkeHUh?=
HGC-27	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH3dZd4UUN3ME2zNU42QDd\|IN88US=>	MmrIV2FPT0WU
GOTO	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXVTWM2OD1\|MT64OVA3KM7:TR?=	MY\TRW5ITVJ?
ChaGo-K-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHGTWM2OD1\|Mj6wNFch\|ryP	NXOwWWRzW0GQR1XS
RO82-W-1	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTN{LkG2NFQh\|ryP	NWrkWHg2W0GQR1XS
SH-4	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7JdoN{UUN3ME2zNk4yQDV6IN88US=>	MVHTRW5ITVJ?
A204	NYSxVG5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7jTWM2OD1\|Mj61NFY6KM7:TR?=	Mn3uV2FPT0WU
DMS-273	NFnrV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7kToVJUUN3ME2zNk42OzJ{IN88US=>	NUnyeGd5W0GQR1XS
KGN	NGD4VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHX[mlKSzVyPUOyMlY{OyEQvF2=	MVrTRW5ITVJ?
SK-MEL-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXEeVdKSzVyPUOyMlY2OjdizszN	MWPTRW5ITVJ?
NCI-H2228	NIrmN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfRTWM2OD1\|Mj62OlAzKM7:TR?=	M3Xtb3NCVkeHUh?=
MKN28	NXvMPJRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTJTWM2OD1\|Mj63PFM5KM7:TR?=	NY\vXXozW0GQR1XS
H-EMC-SS	NYjSU3Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7HNXNzUUN3ME2zNk46Pjd6IN88US=>	MXzTRW5ITVJ?
ATN-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDz[m45UUN3ME2zN{4yPDF4IN88US=>	MmTRV2FPT0WU
D-263MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTN\|LkizO\|gh\|ryP	NUj6WYs3W0GQR1XS
LU-135	NIXnb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPBbHVxUUN3ME2zN{45QDJ7IN88US=>	NVGwNnZsW0GQR1XS
C8166	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS5UXM2UUN3ME2zN{45QDV2IN88US=>	MX3TRW5ITVJ?
T-24	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvqOGRsUUN3ME2zOE4xOjB3IN88US=>	NIPUW3hUSU6JRWK=
Mewo	NXLEcFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XSZmlEPTB;M{SuNVM1QSEQvF2=	MVrTRW5ITVJ?
22RV1	NXH4XoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPVTWM2OD1\|ND6xO\|U1KM7:TR?=	MWnTRW5ITVJ?
KM-H2	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XycWlEPTB;M{SuNVc4QSEQvF2=	NFfFXnZUSU6JRWK=
NCI-H2122	NV\kfmNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;ZN3NKSzVyPUO0MlM1PzFizszN	NFP1d2NUSU6JRWK=
ABC-1	NY\pb4xbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTN2LkO2PVMh\|ryP	M4O2fnNCVkeHUh?=
NCI-H1355	NGDEc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXiZoVKSzVyPUO0MlM5QDlizszN	MWDTRW5ITVJ?
NOMO-1	NXX6SocyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkK0TWM2OD1\|ND61O\|A{KM7:TR?=	M{XUTHNCVkeHUh?=
MZ7-mel	M1WzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIna[HlKSzVyPUO0MlY1QDdizszN	NFjNWpNUSU6JRWK=
NCI-H810	NH;XRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfBRXBKSzVyPUO0MlczPzhizszN	NV\od5NyW0GQR1XS
D-392MG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y4eGlEPTB;M{WuNFU3PSEQvF2=	MUXTRW5ITVJ?
LB771-HNC	NFfaOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Du[2lEPTB;M{WuNVY2QCEQvF2=	NUjH[VExW0GQR1XS
COLO-679	M3:wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWmxVlV2UUN3ME2zOU4{QDhizszN	MUfTRW5ITVJ?
SK-PN-DW	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTN3LkSzOlkh\|ryP	MWXTRW5ITVJ?
VA-ES-BJ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HscGlEPTB;M{WuOFY1QSEQvF2=	NHf6e5hUSU6JRWK=
KNS-42	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT3boRKSzVyPUO1MlU5OjZizszN	NIPkSlNUSU6JRWK=
RVH-421	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37NcWlEPTB;M{WuO\|Y1PSEQvF2=	MlXMV2FPT0WU
P30-OHK	M3ewPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f4emlEPTB;M{WuPFc2OiEQvF2=	MlLVV2FPT0WU
G-402	NEHnRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTN3Lkm4Olch\|ryP	NHvWVpNUSU6JRWK=
S-117	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnJS\|hWUUN3ME2zOk4{ODB6IN88US=>	MW\TRW5ITVJ?
RXF393	M2Xie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi5TWM2OD1\|Nj6zO\|g2KM7:TR?=	NHfMeXZUSU6JRWK=
LCLC-103H	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfDO2s6UUN3ME2zOk44QDB\|IN88US=>	M1rKZXNCVkeHUh?=
U-118-MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\wWJhwUUN3ME2zOk45QDR5IN88US=>	NX;vepZYW0GQR1XS
8-MG-BA	NFrHW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVv3V2V7UUN3ME2zOk46PDh\|IN88US=>	M17VWHNCVkeHUh?=
MFH-ino	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTN5LkOzO\|Eh\|ryP	MYnTRW5ITVJ?
NCI-H23	NEL0fFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzB[JZnUUN3ME2zO{41OTl4IN88US=>	MlHKV2FPT0WU
NCI-H446	M1;DV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW2SlFKSzVyPUO3MlQ5PjJizszN	Mn;IV2FPT0WU
LU-99A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTN5LkW3N\|Eh\|ryP	NWmy[WRFW0GQR1XS
KP-N-YN	NXHZfYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37tRWlEPTB;M{euOlE6PSEQvF2=	MXTTRW5ITVJ?
SCC-9	M4r6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVv2UIM5UUN3ME2zO{44QDN6IN88US=>	NWPURmFuW0GQR1XS
EFM-19	M{G5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTVT\|ZWUUN3ME2zO{44QTZ5IN88US=>	NE\ybVFUSU6JRWK=
A427	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTN5LkmxNFch\|ryP	NGTnc4NUSU6JRWK=
LB831-BLC	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTN6Lk[wN\|kh\|ryP	M3vQenNCVkeHUh?=
HOS	MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTN7Lk[yO\|Mh\|ryP	NIjwbo1USU6JRWK=
LAN-6	NF\5[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTRyLkCxNVIh\|ryP	MUjTRW5ITVJ?
U251	M{DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DBXmlEPTB;NECuOFA2PCEQvF2=	MmLYV2FPT0WU
SNU-387	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H2d2lEPTB;NECuOFU2OyEQvF2=	M1nRSXNCVkeHUh?=
DMS-79	NGDkRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn4S5BKSzVyPUSwMlU5QDlizszN	NGHJOFNUSU6JRWK=
SK-LU-1	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXVOmtKSzVyPUSwMlY2PjhizszN	NIXCd2lUSU6JRWK=
HT	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTRyLk[2N\|kh\|ryP	M4DlXnNCVkeHUh?=
KP-N-YS	NVP6cXdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDOclhWUUN3ME20NE43PzZ6IN88US=>	Ml\iV2FPT0WU
DMS-114	NXTZSmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fqPWlEPTB;NECuPFM4PCEQvF2=	M3LqUXNCVkeHUh?=
HUTU-80	M{n2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRzLkC1Olkh\|ryP	NYrNNZRKW0GQR1XS
ONS-76	NIDnUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf3UYpqUUN3ME20NU41PzB7IN88US=>	MX\TRW5ITVJ?
A673	NHTHPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTRzLkWxOVch\|ryP	NX\D[nA4W0GQR1XS
HPAF-II	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTRzLk[3NFkh\|ryP	M2TaS3NCVkeHUh?=
UACC-257	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYX0bm91UUN3ME20NU44OzZ7IN88US=>	NEHJZpFUSU6JRWK=
EW-22	M2jLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRzLki2PVch\|ryP	M{DNVnNCVkeHUh?=
NCI-H1755	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7MTWM2OD12MT64O\|I2KM7:TR?=	NGHFUldUSU6JRWK=
KYSE-150	NEKyeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn4fVVKSzVyPUSyMlE4QDJizszN	NUPqOHVbW0GQR1XS
CGTH-W-1	M3fuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjBWnQxUUN3ME20Nk41QTV3IN88US=>	MW\TRW5ITVJ?
NB13	NE\1clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfVTWM2OD12Mj62NlE4KM7:TR?=	MmD5V2FPT0WU
SW872	M1zNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjyTWM2OD12Mj62N\|MyKM7:TR?=	M{DJ[nNCVkeHUh?=
KP-4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknVTWM2OD12Mj64PFMzKM7:TR?=	MXPTRW5ITVJ?
HCC38	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTR{Lkm2NVgh\|ryP	MYXTRW5ITVJ?
BB49-HNC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfsTWM2OD12Mz6yN\|U3KM7:TR?=	NFnueYxUSU6JRWK=
CAL-62	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTR\|LkSwNlgh\|ryP	NEHn[YJUSU6JRWK=
NCI-H2029	NXLXPW5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PRNGlEPTB;NEOuOVU5OSEQvF2=	MULTRW5ITVJ?
M14	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln6TWM2OD12ND6xN\|MzKM7:TR?=	NITRO5VUSU6JRWK=
COLO-680N	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTR2LkOzPUDPxE1?	MWrTRW5ITVJ?
Hs-578-T	NI\1NFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n1emlEPTB;NEWuNFI6PCEQvF2=	MUfTRW5ITVJ?
MSTO-211H	NUDJOXZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PXOWlEPTB;NEWuPVQ5OiEQvF2=	MUXTRW5ITVJ?
EW-1	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTR3Lkm2PFkh\|ryP	NGDOT2JUSU6JRWK=
SW948	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTR4LkS0OlIh\|ryP	NW\BNlhHW0GQR1XS
NCI-H460	NXTubGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DBUmlEPTB;NE[uOVI{KM7:TR?=	NX7TbGZzW0GQR1XS
CAS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUj1bWU5UUN3ME20Ok44PzBzIN88US=>	M2e2RnNCVkeHUh?=
TGBC11TKB	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[1WGlEPTB;NEeuNVc4PyEQvF2=	NF;mVopUSU6JRWK=
HD-MY-Z	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTR6Lke4OkDPxE1?	NWX4bWlqW0GQR1XS
NCI-H226	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHONo5XUUN3ME20PU44Pzh3IN88US=>	M3[5fHNCVkeHUh?=
PA-1	NG\1fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTR7LkizN\|Uh\|ryP	MWnTRW5ITVJ?
LB2518-MEL	M1KxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTR7Lki3NlMh\|ryP	MXXTRW5ITVJ?
A101D	NVnE[Jl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;YToVsUUN3ME20PU46PDJ3IN88US=>	M1O2R3NCVkeHUh?=
NCI-H2087	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnhfWhKSzVyPUS5Mlk3QDJizszN	NUPOfHFpW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Active not recruiting	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1
NCT02695290	Terminated	Drug: Afatinib	Carcinoma Non-Small-Cell Lung\|ErbB Receptors	Boehringer Ingelheim	March 17 2016	Phase 4
NCT02171741	Completed	Drug: BIBW 2992\|Drug: Docetaxel	Neoplasms	Boehringer Ingelheim	April 2005	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 180 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 180 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)